The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial

BACKGROUND: We investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase inhibitor (AI) treatment. METHODS: The ABCSG-6a trial re-randomised event-free postmenopausal hormone receptor-positive patients from the ABCSG-6 tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gnant, M, Pfeiler, G, Stöger, H, Mlineritsch, B, Fitzal, F, Balic, M, Kwasny, W, Seifert, M, Stierer, M, Dubsky, P, Greil, R, Steger, G, Samonigg, H, Fesl, C, Jakesz, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738117/
https://www.ncbi.nlm.nih.gov/pubmed/23868011
http://dx.doi.org/10.1038/bjc.2013.367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738117/
https://www.ncbi.nlm.nih.gov/pubmed/23868011
http://dx.doi.org/10.1038/bjc.2013.367

Ejemplares similares